San Francisco-based Sutro Biopharma has inked a deal with Tasly Biopharmaceutical for the development and commercialization of Sutro's antibody-drug conjugate for ovarian and endometrial cancers in Greater China.
STRO-002 is a FolRα-targeting antibody-drug conjugate (ADC), currently in clinical studies for patients with ovarian and endometrial cancers in the U.S. and Europe. It was discovered using Sutro's proprietary and integrated cell-free protein synthesis platform XpressCF and site-specific conjugation platform XpressCF+.
Under the terms of the agreement, Sutro will receive an upfront payment of $40 million and be eligible to receive potentially up to $345 million in development and commercial milestone payments. Shanghai-based Tasly will pursue the clinical development, regulatory approval, and commercialization of STRO-002 in mainland China, Hong Kong, Macau and Taiwan (Greater China) for ovarian and endometrial cancers, with the potential to expand to further oncological indications including non-small cell lung cancer and triple-negative breast cancer.